1
|
Leal I, Nogueira V, Matos DB, Araújo J, Berens O, Ribeiro M, Furtado MJ, Liverani M, Silva MI, Guedes M, Cordeiro M, Ribeiro M, José P, Barão R, Nunes Ferreira R, Fonseca S, Mano S, Pina S, Santos MJ, Fonseca JE, Fonseca C, Figueira L. Design and Development of a Web-Based Prospective Nationwide Registry for Ocular Inflammatory Diseases: UVEITE.PT - The Portuguese Ocular Inflammation Registry. Ocul Immunol Inflamm 2024; 32:342-350. [PMID: 36780588 DOI: 10.1080/09273948.2023.2171891] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2022] [Revised: 01/11/2023] [Accepted: 01/18/2023] [Indexed: 02/15/2023]
Abstract
Uveitis is a heterogeneous collection of infrequent diseases, which poses significant challenges to cost-effective research in the field. Medical registries are being increasingly recognized as crucial tools to provide high-quality data, thus enabling prospective clinical research. This paper describes the design and technical structure development of an innovative countrywide electronic medical record for uveitis, Uveite.pt, and gives an overview of the cohort registered since its foundation, March 2020.Uveite.pt is an electronic medical record platform developed by the Portuguese Ocular Inflammation Group (POIG), a scientific committee of the Portuguese Ophthalmology Society. This is a nationwide customized web-based platform for uveitis patients useful for both clinical practice and real-world-based research, working as a central repository and reporting tool for uveitis. This paper describes the technical principles, the design and the development of a web-based interoperable registry for uveitis in Portugal and provides an overview of more than 400 patients registered in the first 18 months since inception.In infrequent diseases, the existence of registries enables to gather evidence and increase research possibilities to clinicians. The adoption of this platform enables standardization and improvement of clinical practice in uveitis. It is useful to apprehend the repercussion of medical and surgical treatments in uveitis and scleritis, supporting clinicians in the strict monitoring of drug adverse reactions and surgical outcomes.
Collapse
Affiliation(s)
- Inês Leal
- Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Vanda Nogueira
- Instituto de Oftalmologia Dr. Gama Pinto, Lisbon, Portugal
| | - Diogo Bernardo Matos
- Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Joana Araújo
- Ophthalmology Department, Centro Hospitalar Universitário São João, Porto, Portugal
- Departamento de Cirurgia e Fisiologia, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
| | - Olga Berens
- Ophthalmology Department, Hospital do Espírito Santo, Évora, Portugal
| | - Margarida Ribeiro
- Ophthalmology Department, Centro Hospitalar Universitário São João, Porto, Portugal
- Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculdade de Medicina, Universidade do Porto, Porto, Portugal
| | - Maria João Furtado
- Ophthalmology Department, Centro Hospitalar Universitário do Porto, Porto, Portugal
| | - Marco Liverani
- Ophthalmology Department, Hospital de Vila Franca de Xira, Vila Franca de Xira, Portugal
| | - Marta Inês Silva
- Ophthalmology Department, Centro Hospitalar Universitário São João, Porto, Portugal
| | - Marta Guedes
- Ophthalmology Department, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal
| | - Miguel Cordeiro
- Ophthalmology Department, Hospital Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisbon, Portugal
| | - Miguel Ribeiro
- Ophthalmology Department, Centro Hospitalar Tondela-Viseu, Viseu, Portugal
| | - Patrícia José
- Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Rafael Barão
- Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Rui Nunes Ferreira
- Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Sofia Fonseca
- Ophthalmology Department, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal
| | - Sofia Mano
- Ophthalmology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- Centro de Estudos das Ciências da Visão, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Susana Pina
- Ophthalmology Department, Hospital Beatriz Ângelo, Loures, Portugal
| | - Maria José Santos
- Rheumatology Department, Hospital Garcia de Orta, Almada, Portugal
- Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
| | - João Eurico Fonseca
- Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
- Rheumatology Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
| | - Cristina Fonseca
- Ophthalmology Department, Centro de Responsabilidade Integrado de Oftalmologia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
| | - Luís Figueira
- Ophthalmology Department, Centro Hospitalar Universitário São João, Porto, Portugal
- Center for Drug Discovery and Innovative Medicines (MedInUP) of the University of Porto, Porto, Portugal
| |
Collapse
|
2
|
Leal I, Jose P, Barão R, Mano S, Melo AT, Dourado E, Tenazinha C, Vaz C, Ferreira JF, Dinis S, Santos FC, Fernandes H, Khmelinskii N, Marques‐Neves C, de Sousa EV, Fonseca JE. Vision‐related quality of life in spondyloarthritis patients with history of acute anterior uveitis under treatment with golimumab: preliminary results of the GO‐VISION observational study. Acta Ophthalmol 2022. [DOI: 10.1111/j.1755-3768.2022.119] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Ines Leal
- Ophthalmology Faculdade de Medicina de Lisboa Lisbon Portugal
| | - Patricia Jose
- Ophthalmology Faculdade de Medicina de Lisboa Lisbon Portugal
| | - Rafael Barão
- Ophthalmology Faculdade de Medicina de Lisboa Lisbon Portugal
| | - Sofia Mano
- Ophthalmology Faculdade de Medicina de Lisboa Lisbon Portugal
| | - Ana Teresa Melo
- Rheumatology Faculdade de Medicina de Lisboa Lisboa Portugal
| | - Eduardo Dourado
- Rheumatology Faculdade de Medicina de Lisboa Lisboa Portugal
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
José P, Teixeira FJ, Barão R, Sousa DC, Marques RE, Barata ADDO, Marques-Neves C, Alves M, Papoila AL, Stalmans I, Silva JP, Abegão Pinto L. Trabeculectomy with mitomycin C alone or coupled with intracamerular bevacizumab? A 2-year comparative study. Br J Ophthalmol 2021; 106:1399-1405. [PMID: 33931389 DOI: 10.1136/bjophthalmol-2021-319039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 04/04/2021] [Accepted: 04/14/2021] [Indexed: 11/04/2022]
Abstract
PURPOSE To compare outcomes of primary trabeculectomy using either mitomycin C (MMC) alone versus MMC augmented with intracamerular bevacizumab in patients with open-angle glaucoma. METHODS Retrospective, cohort, two-centre, comparative study. Patients' data were screened between October 2015 and March 2019, with inclusion requiring a minimum follow-up of 24 months. Primary outcome was intraocular pressure (IOP) lowering at 24 months, with surgical success defined with different maximum IOP targets (≤18, ≤16 and ≤14 mm Hg) and at least 30% reduction and higher than 5 mm Hg. Absolute success was achieved if no IOP-lowering medication was needed and a qualified success if otherwise. Safety outcomes were analysed. RESULTS A total of 110 eyes underwent trabeculectomy with MMC, 51 of these combined with intracamerular bevacizumab. Both strategies were effective in terms of IOP lowering (baseline vs 2 years postoperatively: 24.4 (8.0) mm Hg vs 12.1 (5.3) mm Hg in the MMC group; 25.1 (8.7) vs 10.8 (3.8) mm Hg in the MMC+bevacizumab group; p<0.001 in both comparisons). The MMC+bevacizumab group had a significant difference towards higher efficacy on absolute success rates at all targets (IOP≤14 or ≤16 or ≤18 mm Hg; p=0.010, p=0.039 and p=0.007, respectively). The large majority (93%) of the MMC+bevacizumab group was drop-free at 24 months, and 41% had IOP below 10 mm Hg. Complication rates were low and similar between groups, with no systemic adverse events. CONCLUSIONS Intracamerular bevacizumab in MMC-augmented primary trabeculectomy increases the chances of obtaining low IOP outcomes. This strategy may be useful when planning for surgeries aiming at target pressures in the low teens. TRIAL REGISTRATION NUMBER ISRCTN93098069.
Collapse
Affiliation(s)
- Patrícia José
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal .,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Filipa Jorge Teixeira
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Rafael Barão
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - David Cordeiro Sousa
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.,Vision Sciences Study Center, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Vitreoretinal Unit, Royal Victorian Eye and Ear Hospital, Melbourne, VIC, Australia
| | - Raquel Esteves Marques
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
| | - Andre Diogo De Oliveira Barata
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.,Ophthalmology, Hospital Lusíadas Lisboa, Lisboa, Portugal
| | - Carlos Marques-Neves
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.,Vision Sciences Study Center, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
| | - Marta Alves
- CEAUL, Biostatistics Department, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal
| | - Ana Luísa Papoila
- CEAUL, Biostatistics Department, NOVA Medical School, Universidade Nova de Lisboa, Lisbon, Portugal
| | | | | | - Luis Abegão Pinto
- Ophthalmology, Centro Hospitalar Lisboa Norte, Lisboa, Portugal.,Ophthalmology University Clinic, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.,Vision Sciences Study Center, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal.,Ophthalmology, Hospital Lusíadas Lisboa, Lisboa, Portugal
| |
Collapse
|
4
|
Teixeira FJ, Sousa DC, Machado NM, Caiado F, Barão R, Sens P, Abegão Pinto L. XEN-augmented Baerveldt surgical success rate and comparison with the Ahmed Valve. Acta Ophthalmol 2020; 98:e870-e875. [PMID: 32187846 DOI: 10.1111/aos.14400] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2019] [Revised: 02/03/2020] [Accepted: 02/21/2020] [Indexed: 11/30/2022]
Abstract
PURPOSE The Baerveldt-XEN technique is intended to reduce the risk of early hypotony after Baerveldt implant, while keeping a good long-term intra-ocular pressure (IOP) control. The aim of this study is to discuss the surgical success rate of the Baerveldt-XEN and compare it with the commercially available flow-restrictor device (Ahmed glaucoma valve - AGV). METHODS Single-centre, cohort study. Consecutive glaucoma patients with uncontrolled IOP > 21 mmHg on maximum tolerated medical therapy, and who had an aqueous shunt as the planned surgical procedure. Patients underwent implantation of Baerveldt-XEN. An age-, gender- and glaucoma aetiology-matched database of AGV patients was used for comparison. Complete surgical success was defined as a final IOP between 6 and 21 mmHg, and 20% reduction from baseline with no need for IOP-lowering medication. Qualified success was the same criteria but resorting to medications. RESULTS Twenty-four eyes from 24 subjects with glaucoma were included in this study, 12 patients underwent Baerveldt-XEN implantation and 12 AGV. Twelve months after the Baerveldt-XEN implant, the IOP reduced from 33 ± 9 mmHg to 14 ± 3 mmHg (p < 0.001). The qualified and complete success rate was 50% and 25%, respectively. With the AGV, the IOP reduced from 29 ± 7 mmHg to 16 ± 7 mmHg (p = 0.001). The matched AGV group compared to the Baerveldt-XEN, presented a higher complete success rate (58.3%) and a qualified success rate of 33.3% (p = 0.72). No sight-threatening complications were recorded in both groups. CONCLUSIONS The Baerveldt-XEN disclosed a low complete success rate at 1 year of follow-up, although with no major safety concerns. While studies with a longer follow-up are needed to demonstrate the potential advantages and disadvantages of the Baerveldt-XEN, this technique may be less likely to achieve drop-free efficacy when compared to other flow-restrictor strategies.
Collapse
Affiliation(s)
- Filipa Jorge Teixeira
- Serviço de Oftalmologia Hospital de Santa Maria Lisboa Portugal
- Clínica Universitária de Oftalmologia Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
| | - David Cordeiro Sousa
- Serviço de Oftalmologia Hospital de Santa Maria Lisboa Portugal
- Clínica Universitária de Oftalmologia Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
- Centro de Estudos Ciências da Visão Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
| | | | - Filipa Caiado
- Serviço de Oftalmologia Hospital de Santa Maria Lisboa Portugal
- Clínica Universitária de Oftalmologia Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
| | - Rafael Barão
- Serviço de Oftalmologia Hospital de Santa Maria Lisboa Portugal
- Clínica Universitária de Oftalmologia Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
| | - Paula Sens
- Serviço de Oftalmologia Hospital de Santa Maria Lisboa Portugal
- Clínica Universitária de Oftalmologia Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
| | - Luís Abegão Pinto
- Serviço de Oftalmologia Hospital de Santa Maria Lisboa Portugal
- Clínica Universitária de Oftalmologia Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
- Centro de Estudos Ciências da Visão Faculdade de Medicina Universidade de Lisboa Lisboa Portugal
| |
Collapse
|